cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fate Therapeutics Inc
16 own
13 watching
Current Price
$3.7
$-0.21
(-5.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
245.43M
52-Week High
52-Week High
8.83000
52-Week Low
52-Week Low
1.63000
Average Volume
Average Volume
2.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization245.43M
icon52-Week High8.83000
icon52-Week Low1.63000
iconAverage Volume2.02M
iconDividend Yield--
iconP/E Ratio--
What does the Fate Therapeutics Inc do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
How much money does Fate Therapeutics Inc make?
News & Events about Fate Therapeutics Inc.
Business Wire
11 months ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a...
Globe Newswire
11 months ago
NEW YORK, June 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRTK to Gurnet Point Capital and Novo Holdings A/S for $2.15 per share in cash, plus a CVR of...
Business Wire
11 months ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a...
Benzinga
1 year ago
read more...
Globe Newswire
1 year ago
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ: CRBU) Johnson Fistel, LLP is investigating potential claims on behalf of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) against certain of its officers and directors. If you are a current, long-term...
Frequently Asked Questions
Frequently Asked Questions
What is Fate Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Fate Therapeutics Inc shares?
plus_minus_icon
How can I buy Fate Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Fate Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fate Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Fate Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Fate Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fate Therapeutics Inc?
plus_minus_icon
What percentage is Fate Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fate Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.7
$-0.21
(-5.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00